prophetic article, page-23

Jevalent,

Your point re Ventracor is very salient. Shareholders thought they could resurrect that, too.

Metabolic shareholders were also outraged that the anti-obesity pill was scrapped. That one is still swimming in limbo, although, I am pretty sure it is dead.

PI-88 was hyped by Progen as much as ATC was by Avexa. After scrapping PI-88, the board finally gave it away to a Taiwanese company to get a group of shareholders off their back. The Taiwanese company is now hoping for a "regional" deal.

Phenoxodiol, which was dumped in a similar manner to ATC, recently, also looks dead and buried despite calls from shareholders to breathe new life into it.

Boards almost always hang out for deal for their lead product until well after all avenues have been exhausted, because they know that killing the golden goose will pretty much kill the company. Eventually, they have to do it, though, otherwise they will have no chance at all of retaining their job.

History, tells me that ATC is dead and that nothing as simple as a meeting with the FDA is going to solve that.

If I were an Avexa shareholder, I would be looking to the future and not the past.

Actually, that is not true. I would sell out and take the overs on offer above cash backing.

Bill